230 related articles for article (PubMed ID: 35484422)
1. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F
Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422
[TBL] [Abstract][Full Text] [Related]
2.
Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
[No Abstract] [Full Text] [Related]
3. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma.
Lu Y; Yang Q; Su Y; Ji Y; Li G; Yang X; Xu L; Lu Z; Dong J; Wu Y; Bei JX; Pan C; Gu X; Li B
Cell Death Dis; 2021 May; 12(6):511. PubMed ID: 34011924
[TBL] [Abstract][Full Text] [Related]
4. MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in
Floros KV; Chawla AT; Johnson-Berro MO; Khatri R; Stamatouli AM; Boikos SA; Dozmorov MG; Cowart LA; Faber AC
Cell Stress; 2022 Feb; 6(2):21-29. PubMed ID: 35174317
[TBL] [Abstract][Full Text] [Related]
5. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
Alborzinia H; Chen Z; Yildiz U; Freitas FP; Vogel FCE; Varga JP; Batani J; Bartenhagen C; Schmitz W; Büchel G; Michalke B; Zheng J; Meierjohann S; Girardi E; Espinet E; Flórez AF; Dos Santos AF; Aroua N; Cheytan T; Haenlin J; Schlicker L; Xavier da Silva TN; Przybylla A; Zeisberger P; Superti-Furga G; Eilers M; Conrad M; Fabiano M; Schweizer U; Fischer M; Schulze A; Trumpp A; Friedmann Angeli JP
EMBO Mol Med; 2023 Aug; 15(8):e18014. PubMed ID: 37435859
[TBL] [Abstract][Full Text] [Related]
6. 4-Hydroxychalcone Induces Cell Death via Oxidative Stress in
Alshangiti AM; Tuboly E; Hegarty SV; McCarthy CM; Sullivan AM; O'Keeffe GW
Oxid Med Cell Longev; 2019; 2019():1670759. PubMed ID: 31885773
[TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax-based Rational Combinations are Effective in Models of
Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
[TBL] [Abstract][Full Text] [Related]
9. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
10. Ferroptosis vulnerability in MYCN-driven neuroblastomas.
Dasgupta S; Gan B
Clin Transl Med; 2022 Aug; 12(8):e963. PubMed ID: 35908258
[No Abstract] [Full Text] [Related]
11. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
12. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
13. The super elongation complex drives transcriptional addiction in
Wang D; Yin Z; Wang H; Wang L; Li T; Xiao R; Xie T; Han R; Dong R; Liu H; Liang K; Qing G
Sci Adv; 2023 Mar; 9(13):eadf0005. PubMed ID: 36989355
[No Abstract] [Full Text] [Related]
14. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
15. FOXR2 Stabilizes MYCN Protein and Identifies Non-
Schmitt-Hoffner F; van Rijn S; Toprak UH; Mauermann M; Rosemann F; Heit-Mondrzyk A; Hübner JM; Camgöz A; Hartlieb S; Pfister SM; Henrich KO; Westermann F; Kool M
J Clin Oncol; 2021 Oct; 39(29):3217-3228. PubMed ID: 34110923
[TBL] [Abstract][Full Text] [Related]
16. PRIMA-1
Mlakar V; Jurkovic Mlakar S; Lesne L; Marino D; Rathi KS; Maris JM; Ansari M; Gumy-Pause F
J Exp Clin Cancer Res; 2019 Feb; 38(1):69. PubMed ID: 30755224
[TBL] [Abstract][Full Text] [Related]
17. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
18. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
20. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
